Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative phosphoproteomics of chronic sunitinib treated renal cell carcinoma 786-O cells with GPR30 agonist G-1

ABSTRACT: In this project, we generated chronic sunitinib-treated 786-O cell, a renal cell carcinoma cell line. In order to investigate the possible effect of GPR30 agonist, G-1, on the growth-inhibtion related signaling pathways, we treated either parental both parental and chronic sunitinib-treated 786-O cells were treated either by vehicle-only (i.e. 0.1% DMSO) or 2 μM G-1 for 48 h. Therefore, there were three groups for comparison, including G-1 treatment (G-1 vs. parental), chronic sunitinib-treatment (SunR vs. parental), and G-1 treatment in SunR cells (SunR&G-1 vs. parental).

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Wei-Chi Ku

PROVIDER: PXD020904 | JPOST Repository | Sat Aug 14 00:00:00 BST 2021

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Similar Datasets

Quantitative phosphoproteomics of chronic sunitinib treated renal cell carcinoma 786-O cells with GPR30 agonist G-1

Project description:In this project, we generated chronic sunitinib-treated 786-O cell, a renal cell carcinoma cell line. In order to investigate the possible effect of GPR30 agonist, G-1, on the growth-inhibtion related signaling pathways, we treated either parental both parental and chronic sunitinib-treated 786-O cells were treated either by vehicle-only (i.e. 0.1% DMSO) or 2 μM G-1 for 48 h. Therefore, there were three groups for comparison, including G-1 treatment (G-1 vs. parental), chronic sunitinib-treatment (SunR vs. parental), and G-1 treatment in SunR cells (SunR&G-1 vs. parental).

2021-04-28 | PXD021254 | Pride

Chronic Rapamycin treated bone marrow dendritic cells

Project description:Bone marrow dendritic cells were propaged with chronic treatment with Rapamycin and compared to vehicle treated cells.

2021-07-15 | GSE158161 | GEO

AHR ChIP-seq in primary human hepatocytes treated with TCDD

Project description:ChIP-seq was done on cryopreserved primary human hepatocyte with vehicle control - 0.1% dimethylsulfide (DMSO), or 1nM 2,3,7,8 tetrachlorodibezno-p-dioxin (TCDD) agonist treatment to identify AHR binding regions throughout the genome. We identified 1,984 binding peaks when comparing TCDD vs. vehicle control

2022-06-09 | GSE205502 | GEO

Chronic Rosiglitazone Mouse Aorta

Project description:To better understand what genes are regulated by PPAR gamma, an experimental dataset was generated by microarray analysis, in duplicate, of pooled aortic mRNA isolated from adult male mice (C57BL/6J strain) treated for 21 days with a PPAR gamma agonist (rosiglitazone) or vehicle. Keywords: other

2004-03-19 | GSE1011 | GEO

chronic carnitine treatment (negative mode)

Project description:Samples from mice infected and then treated with vehicle, carnitine or benznidazole in the chronic stage of infection. Tissue samples extracted with 50% methanol followed by 3:1 dichloromethane:methanol. C8 chromatography with negative mode data acquisition

2023-11-13 | MSV000093394 | MassIVE

Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy

Project description:Chronic stimulation of cardiac a1A-adrenergic receptors (a1A-ARs) improves symptoms in multiple preclinical models of heart failure. However, the translational significance remains unclear. This study tested the effects of chronic a1A-AR stimulation on human engineered heart tissue (EHT). EHTs were created from thin slices of decellularized pig myocardium seeded with human induced pluripotent stem cell (iPSC)-derived cardiomyocytes and fibroblasts. Using a paired experimental design, EHTs were cultured for 3 wk., mechanically tested, cultured again for 2 wk. with a1A-AR agonist A61603 (10 nM) or vehicle control, and retested after drug washout for 24-hr. Separate control experiments determined the effects of EHT age (3-5 wk.) or repeat mechanical testing. We found that chronic A61603 treatment caused a 25% increase of length-dependent activation (LDA) of contraction compared to vehicle treatment (n=7/group, P=0.035). EHT force was not increased after chronic A61603 treatment. However, after vehicle treatment, EHT force was increased 35% relative to baseline testing (n=7/group, P=0.022), suggesting EHT maturation. Control experiments showed increased EHT force resulted from repeat mechanical testing, not from EHT aging. RNA-seq analysis confirmed the a1A-AR is expressed in human EHTs and found chronic A61603 treatment affected gene expression in biological pathways which are known to be activated by a1A-ARs, including the MAP kinase signaling pathway. In conclusion, chronic stimulation of the a1A-AR, a promising preclinical target for treating heart failure, gave mixed results in human EHTs. Chronic a1A-AR stimulation had a positive effect (increased LDA) but potentially, a negative effect (lower EHT force). The translational significance of these findings requires further study.

2023-01-01 | GSE216439 | GEO

Expression profiles of Telomerase+ vs. ALT+ G3 Atm-/-TERT-ER T-cell lymphomas

Project description:We used microarray profiling to document the difference between telomerase+ vs. ALT+ T-cell lymphomas developed on G3 Atm-/-TERT-ER genetic background. T-cell lymphomas were developed in G3 Atm-/-TERT-ER mice with 4-OHT treatment. These cells were either maintained on SCID mice treated with 4-OHT or vehicle. Cells maintained on vehicle eventually developed ALT-dependent resistance. We used microarray to profile telomerase+ tumors vs. ALT+ tumors from the same parental lines.

2012-01-17 | E-GEOD-35044 | biostudies-arrayexpress

Transcriptomic profile of normal immortalized fallopian tube cells in response to long-term norepinephrine treatment

Project description:The goal of this study was to identify transcriptional changes that occur in response to long-term norepinephrine (NE) treatment on normal immortalized fallopian tube cells (iFTSEC283). We treated isogenic cell lines (iFTSEC283 and iFTSEC283p53R175H) with 10μM NE or vehicle control (water) for 137 days with media change every two days followed by whole-transcriptome RNA seq. We identified 123 differentially expressed genes in 10μM NE vs mock-treated iFTSEC283. In iFTSEC283p53R175H cells, we identified 23 differentially expressed genes in response to chronic NE treatment.

2021-03-08 | GSE168097 | GEO

Expression data of glioblastoma cells with Crizotinib acute and chronic treatment vs its own vehicle control

Project description:Gene expression of chronically or acutely Crizotinib treated glioblastoma cells vs vehicle controls

2020-04-22 | GSE113961 | GEO

Genomic copy number profiling of different generations of Atm-/-TERT-ER T-cell lymphomas and associated resistant tumors following telomerase inhibition

Project description:Genomic copy numbers of various generations of Atm-/-TERT-ER mice treated with 4-OHT or vehicle were profiled. Genomic copy numbers of transplanted G3 Atm-/-TERT-ER T-cell lymphomas with telomerase or ALT T-cell lymphomas were developed in various generations of Atm-/-TERT-ER mice with 4-OHT or vehicle treatment. These tumors were profiled with aCGH. G3 Atm-/-TERT-ER tumors were transplanted into SCID mice treated with 4-OHT or vehicle. Cells maintained on vehicle eventually developed ALT-dependent resistance. We used aCGH to profile telomerase+ tumors vs. ALT+ tumors from the same parental lines.

2012-01-17 | E-GEOD-35045 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data